{
  "id": 11136474,
  "title": "JPMorgan initiates Spyre stock with Overweight on IBD pipeline",
  "url": "https://urgent.news/2026/10/01/jpmorgan-initiates-spyre-stock-with-overweight-on-ibd-pipeline",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-10-01T07:32:55.000Z",
  "source": {
    "name": "Investing.com",
    "slug": "investing-com",
    "url": "https://www.investing.com/news/analyst-ratings/jpmorgan-initiates-spyre-stock-with-overweight-on-ibd-pipeline-93CH-4926445"
  },
  "original_language": "en",
  "account": null,
  "summary": "JPMorgan has initiated coverage on Spyre Therapeutics Inc. (NASDAQ:SYRE) with an Overweight rating and a price target of $110.00, following the biotech company's remarkable 441% gain over the past year. Spyre is developing six clinical-stage assets for inflammatory bowel disease (IBD), including three monotherapies targeting α4β7, TL1A, and IL-23. Analyst Hardik Parikh believes that the company's combination therapies could differentiate them from competitors by providing convenience and less frequent dosing. JPMorgan projects that Spyre can capture a low-teens percentage share of the U.S. advanced biologics IBD market by the 2040s, resulting in annual worldwide sales of $6 billion to $7 billion. Despite the company's strong liquidity and lack of profitability this year, analysts do not expect profitability this year, which is typical for clinical-stage biotech firms.",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 2,
    "also_reported_by": [
      {
        "outlet": "Investing.com",
        "title": "Enliven Therapeutics stock initiated at Overweight by JPMorgan",
        "url": "https://urgent.news/2026/10/01/enliven-therapeutics-stock-initiated-at-overweight-by-jpmorgan",
        "published": "2026-10-01T07:32:47.000Z"
      }
    ]
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}